GlassScriptPhysician profile
Nichole Palomba
NPI 1124494661
$4,154.05
in general payments reported to CMS, 2019-2025
20 companies · $873 in 2025
The $873 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,084 · 2024: $2,196 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,974 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,974.07 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $534.91 | 2023-2024 | Sotyktu |
| Janssen Biotech, INC. | $524.55 | 2023-2025 | Tremfya |
| Galderma Laboratories, L.P. | $500.75 | 2023-2025 | Aklief, Nemluvio, Oracea |
| Arcutis Biotherapeutics, INC. | $360.59 | 2023-2025 | Zoryve |
| Abbvie INC. | $357.30 | 2023-2025 | |
| Amgen INC. | $350.26 | 2023-2024 | Otezla |
| Incyte Corporation | $328.08 | 2023-2025 | Opzelura |
| Ucb, INC. | $211.68 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $181.30 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Pfizer INC. | $135.78 | 2024 | |
| Leo Pharma INC. | $109.03 | 2023-2024 | Adbry |
| Paratek Pharmaceuticals, INC. | $103.90 | 2023-2024 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $84.94 | 2024 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $83.68 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $76.12 | 2023 | Vtama |
| Tempus Ai, INC | $54.96 | 2024 | |
| Genzyme Corporation | $27.75 | 2024 | |
| Verrica Pharmaceuticals INC. | $24.98 | 2024 | Ycanth |
| Biofrontera INC. | $23.50 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nichole Palomba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.